Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Similarities in serum acylcarnitine patterns in type 1 and type 2 diabetes mellitus and in metabolic syndrome.

Bene J, Márton M, Mohás M, Bagosi Z, Bujtor Z, Oroszlán T, Gasztonyi B, Wittmann I, Melegh B.

Ann Nutr Metab. 2013;62(1):80-5. doi: 10.1159/000345759. Epub 2012 Dec 28.

PMID:
23296094
2.

Haplotype analysis of the apolipoprotein A5 gene in patients with the metabolic syndrome.

Kisfali P, Mohás M, Maász A, Polgár N, Hadarits F, Markó L, Brasnyó P, Horvatovich K, Oroszlán T, Bagosi Z, Bujtor Z, Gasztonyi B, Rinfel J, Wittmann I, Melegh B.

Nutr Metab Cardiovasc Dis. 2010 Sep;20(7):505-11. doi: 10.1016/j.numecd.2009.05.001. Epub 2009 Aug 18.

PMID:
19692219
3.

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F.

N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6.

4.

Apolipoprotein A5 IVS3+476A allelic variant associates with increased trigliceride levels and confers risk for development of metabolic syndrome in Hungarians.

Kisfali P, Mohás M, Maasz A, Hadarits F, Markó L, Horvatovich K, Oroszlán T, Bagosi Z, Bujtor Z, Gasztonyi B, Wittmann I, Melegh B.

Circ J. 2008 Jan;72(1):40-3.

5.

[The role of continuous glucose monitoring in the therapy of diabetes mellitus].

Bagosi Z, Oroszlán T, Bujtor Z, Gasztonyi B.

Orv Hetil. 2007 Oct 14;148(41):1923-8. Hungarian.

PMID:
17921119

Supplemental Content

Loading ...
Support Center